Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Castelli

Showing results (281-290 of 291) with videos related to

Pageof 30
Sort By:
American Journal of Medical Genetics. Part A|March 29, 2019
Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT studyDerralynn A Hughes, Kathleen Nicholls, Gere Sunder-Plassmann, et al.
Biorxiv : the Preprint Server for Biology|July 14, 2025
<i>In vivo</i> production of an anti-HIV antibody from primate hematopoietic cells by non-viral knock-inJack M P Castelli, Katrina Poljakov, Youngseo Jwa, et al.
Current Medicinal Chemistry|July 19, 2013
The new compound GET73, N-[(4-trifluoromethyl)benzyl]4-methoxybutyramide, Regulates hippocampal Aminoacidergic transmission possibly via an allosteric modulation of mGlu5 receptor. Behavioural evidence of its "anti-alcohol" and anxiolytic propertiesL Ferraro, A Loche, S Beggiato, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|February 7, 2019
Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension studyDominique P Germain, Kathy Nicholls, Roberto Giugliani, et al.
Gene Therapy|January 14, 2026
CRISPR-AuNP: physicochemical optimization of a gold nanoparticle platform for cost-effective and modular non-viral gene editing in HSPCsKarthikeya S V Gottimukkala, Daniel D Lane, Rachel Cunningham, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 4, 2011
Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009S Di Giambenedetto, M Prosperi, I Fanti, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 4, 2026
In vivo production of an anti-HIV antibody in mice by non-viral gene knock-in in primate hematopoietic stem and progenitor cellsJack M P Castelli, Katrina Poljakov, Youngseo Jwa, et al.
Orphanet Journal of Rare Diseases|April 29, 2018
Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trialRaphael Schiffmann, Daniel G Bichet, Ana Jovanovic, et al.
Nature Communications|July 2, 2024
Cyprocide selectively kills nematodes via cytochrome P450 bioactivationJessica Knox, Andrew R Burns, Brittany Cooke, et al.
Science (New York, N.Y.)|October 30, 2025
The functional landscape of coding variation in the familial hypercholesterolemia gene <i>LDLR</i>Daniel R Tabet, Atina G Coté, Megan C Lancaster, et al.
Pageof 30

Showing results (281-290 of 291) with videos related to

Sort By:
Pageof 30
American Journal of Medical Genetics. Part A|March 29, 2019
Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT studyDerralynn A Hughes, Kathleen Nicholls, Gere Sunder-Plassmann, et al.
Biorxiv : the Preprint Server for Biology|July 14, 2025
<i>In vivo</i> production of an anti-HIV antibody from primate hematopoietic cells by non-viral knock-inJack M P Castelli, Katrina Poljakov, Youngseo Jwa, et al.
Current Medicinal Chemistry|July 19, 2013
The new compound GET73, N-[(4-trifluoromethyl)benzyl]4-methoxybutyramide, Regulates hippocampal Aminoacidergic transmission possibly via an allosteric modulation of mGlu5 receptor. Behavioural evidence of its "anti-alcohol" and anxiolytic propertiesL Ferraro, A Loche, S Beggiato, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|February 7, 2019
Efficacy of the pharmacologic chaperone migalastat in a subset of male patients with the classic phenotype of Fabry disease and migalastat-amenable variants: data from the phase 3 randomized, multicenter, double-blind clinical trial and extension studyDominique P Germain, Kathy Nicholls, Roberto Giugliani, et al.
Gene Therapy|January 14, 2026
CRISPR-AuNP: physicochemical optimization of a gold nanoparticle platform for cost-effective and modular non-viral gene editing in HSPCsKarthikeya S V Gottimukkala, Daniel D Lane, Rachel Cunningham, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 4, 2011
Update on emergence of HIV-1 resistance to antiretroviral drug classes in an Italian national database: 2007-2009S Di Giambenedetto, M Prosperi, I Fanti, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|February 4, 2026
In vivo production of an anti-HIV antibody in mice by non-viral gene knock-in in primate hematopoietic stem and progenitor cellsJack M P Castelli, Katrina Poljakov, Youngseo Jwa, et al.
Orphanet Journal of Rare Diseases|April 29, 2018
Migalastat improves diarrhea in patients with Fabry disease: clinical-biomarker correlations from the phase 3 FACETS trialRaphael Schiffmann, Daniel G Bichet, Ana Jovanovic, et al.
Nature Communications|July 2, 2024
Cyprocide selectively kills nematodes via cytochrome P450 bioactivationJessica Knox, Andrew R Burns, Brittany Cooke, et al.
Science (New York, N.Y.)|October 30, 2025
The functional landscape of coding variation in the familial hypercholesterolemia gene <i>LDLR</i>Daniel R Tabet, Atina G Coté, Megan C Lancaster, et al.
Pageof 30